Clinical Trials Browser

Completed × Has results × relugolix × Clear all

NCT04523207 2025-04-25

A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases

Phase 2 Completed

108 enrolled 13 charts

Prostatic Neoplasms

NCT03751124 2024-06-25

Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Phase 3 Completed

229 enrolled 66 charts

Leiomyoma, Menorrhagia, Myofibroma

NCT03103087 2022-04-20

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Phase 3 Completed

382 enrolled 57 charts

Leiomyoma, Menorrhagia

NCT03085095 2022-01-18

HERO

Phase 3 Completed

1,134 enrolled 38 charts 2 FDA

Prostatic Neoplasms

NCT02655224 2019-03-22

A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids

Phase 3 Completed

65 enrolled 28 charts

Leiomyoma

NCT02083185 2018-05-09

A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer

Phase 2 Completed

136 enrolled 26 charts

Prostatic Neoplasms

NCT02135445 2017-04-13

Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer

Phase 2 Completed

103 enrolled 42 charts

Prostatic Neoplasms

NCT02093390 2016-06-06

A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects

Phase 1 Completed

40 enrolled 23 charts

Endometriosis, Prostatic Neoplasms